Citigroup’s Regenxbio RGNX Stock Holding History

Citigroup’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$270K	Sell	22,500 -27,000	-55%	-$224K	﹤0.01%	4191
2026 Q1	$415K	Buy	+49,500	New	+$520K	﹤0.01%	3651
2025 Q1	–	Sell	-24,900	Closed	-$192K	–	5896
2024 Q4	$192K	Sell	24,900 -100	-0.4%	-$939	﹤0.01%	4439
2024 Q3	$262K	Buy	+25,000	New	+$305K	﹤0.01%	4154
2023 Q4	–	Sell	-50,000	Closed	-$823K	–	5832
2023 Q3	$823K	Buy	50,000 +25,100	+101%	+$455K	﹤0.01%	2670
2023 Q2	$498K	Buy	+24,900	New	+$480K	﹤0.01%	3372
2019 Q3	–	Sell	-3,800	Closed	-$195K	–	7799
2019 Q2	$195K	Sell	3,800 -15,000	-80%	-$749K	﹤0.01%	5296
2019 Q1	$1.08M	Sell	18,800 -10,700	-36%	-$530K	﹤0.01%	3323
2018 Q4	$1.24M	Buy	+29,500	New	+$1.73M	﹤0.01%	3178

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Citigroup's RGNX Position: Q2 2026 in Review

Citigroup increased its Regenxbio (RGNX) stake by 204% in Q2 2026, buying an estimated $435K and bringing the position to 78,022 shares worth $935K. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

Citigroup first reported a position in RGNX in Q4 2015 and has held it in 43 quarters since. The position peaked at $13.5M in Q2 2018. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Citigroup held 78,022 shares of Regenxbio worth $935K as of Q2 2026.
Citigroup bought 52,372 Regenxbio shares in Q2 2026, an estimated $435K.
Regenxbio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3501 holding.
Citigroup first reported a position in Regenxbio in Q4 2015 and has held it in 43 quarters since.
Citigroup's Regenxbio position peaked at $13.5M in Q2 2018.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.